First Horizon Advisors Inc. Purchases 342 Shares of Roche Holding AG (OTCMKTS:RHHBY)

First Horizon Advisors Inc. boosted its position in shares of Roche Holding AG (OTCMKTS:RHHBY) by 19.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,066 shares of the company’s stock after purchasing an additional 342 shares during the period. First Horizon Advisors Inc.’s holdings in Roche were worth $75,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Altrius Capital Management Inc raised its holdings in shares of Roche by 2.5% in the third quarter. Altrius Capital Management Inc now owns 171,062 shares of the company’s stock worth $5,804,000 after buying an additional 4,232 shares during the period. Enterprise Financial Services Corp purchased a new stake in Roche in the third quarter worth $288,000. Paradigm Asset Management Co. LLC lifted its position in shares of Roche by 18.4% during the third quarter. Paradigm Asset Management Co. LLC now owns 5,151 shares of the company’s stock worth $175,000 after purchasing an additional 800 shares during the last quarter. Tower Bridge Advisors purchased a new stake in shares of Roche during the third quarter valued at $2,811,000. Finally, Motco grew its holdings in shares of Roche by 612.7% in the third quarter. Motco now owns 4,426 shares of the company’s stock worth $151,000 after purchasing an additional 3,805 shares during the last quarter.

Roche Price Performance

OTCMKTS:RHHBY opened at $30.48 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.75. The company has a 50-day moving average of $31.52 and a 200 day moving average of $33.38. Roche Holding AG has a 1-year low of $29.20 and a 1-year high of $40.48.

Analysts Set New Price Targets

RHHBY has been the subject of a number of research analyst reports. Morgan Stanley lowered shares of Roche from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 16th. Argus reaffirmed a “hold” rating on shares of Roche in a research note on Monday, March 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Roche currently has an average rating of “Hold” and an average target price of $40.00.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.